黑色素-话题@MedSci

#黑色素#

1110篇内容 | 3064人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1559133, encodeId=c32d155913336, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=ASCO：四周的MPRbx可作为晚期黑色素瘤治疗反应的早期生物标志物, objectType=article, longId=728229, objectId=e1ace28229dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1ace28229dc, replyNumber=0, likeNumber=70, createdTime=2022-06-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1ace28229dc, moduleTitle=ASCO：四周的MPRbx可作为晚期黑色素瘤治疗反应的早期生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1ace28229dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565142, encodeId=f56c1565142fe, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=ASCO：四周的MPRbx可作为晚期黑色素瘤治疗反应的早期生物标志物, objectType=article, longId=728229, objectId=e1ace28229dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1ace28229dc, replyNumber=0, likeNumber=63, createdTime=2022-06-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1ace28229dc, moduleTitle=ASCO：四周的MPRbx可作为晚期黑色素瘤治疗反应的早期生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1ace28229dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559134, encodeId=8ddb1559134fd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, objectType=article, longId=728227, objectId=6d23e28227bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d23e28227bf, replyNumber=0, likeNumber=108, createdTime=2022-06-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d23e28227bf, moduleTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d23e28227bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565143, encodeId=b9f515651433f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, objectType=article, longId=728227, objectId=6d23e28227bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d23e28227bf, replyNumber=0, likeNumber=97, createdTime=2022-06-01, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d23e28227bf, moduleTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d23e28227bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559136, encodeId=47f715591362e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果, objectType=article, longId=728226, objectId=c05ae282264e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c05ae282264e, replyNumber=0, likeNumber=65, createdTime=2022-06-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c05ae282264e, moduleTitle=ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c05ae282264e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565145, encodeId=0c3d1565145b1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果, objectType=article, longId=728226, objectId=c05ae282264e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c05ae282264e, replyNumber=0, likeNumber=63, createdTime=2022-06-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c05ae282264e, moduleTitle=ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c05ae282264e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559131, encodeId=527a15591313c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, objectType=article, longId=726495, objectId=d831e2649564, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d831e2649564, replyNumber=0, likeNumber=65, createdTime=2022-05-11, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d831e2649564, moduleTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d831e2649564)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565140, encodeId=780515651406d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, objectType=article, longId=726495, objectId=d831e2649564, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d831e2649564, replyNumber=0, likeNumber=69, createdTime=2022-05-11, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d831e2649564, moduleTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d831e2649564)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559130, encodeId=fdc8155913086, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JGH:长期使用硫嘌呤不会增加炎症性肠病患者淋巴瘤和非黑色素瘤皮肤癌的风险, objectType=article, longId=726395, objectId=f5b7e2639539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5b7e2639539, replyNumber=0, likeNumber=58, createdTime=2022-05-10, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5b7e2639539, moduleTitle=JGH:长期使用硫嘌呤不会增加炎症性肠病患者淋巴瘤和非黑色素瘤皮肤癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5b7e2639539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565139, encodeId=14d71565139c7, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JGH:长期使用硫嘌呤不会增加炎症性肠病患者淋巴瘤和非黑色素瘤皮肤癌的风险, objectType=article, longId=726395, objectId=f5b7e2639539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5b7e2639539, replyNumber=0, likeNumber=73, createdTime=2022-05-10, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5b7e2639539, moduleTitle=JGH:长期使用硫嘌呤不会增加炎症性肠病患者淋巴瘤和非黑色素瘤皮肤癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5b7e2639539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559129, encodeId=4d921559129c1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, objectType=article, longId=726015, objectId=0c7fe2601525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7fe2601525, replyNumber=0, likeNumber=80, createdTime=2022-05-04, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7fe2601525, moduleTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c7fe2601525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565138, encodeId=104715651386c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, objectType=article, longId=726015, objectId=0c7fe2601525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7fe2601525, replyNumber=0, likeNumber=59, createdTime=2022-05-04, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7fe2601525, moduleTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c7fe2601525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559128, encodeId=2aa9155912846, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=AACR重磅之SPOTLIGHT203试验：瘤内注射BO-112联合帕博丽珠单抗对PD-1免疫治疗耐药的晚期黑色素瘤患者的疗效, objectType=article, longId=723987, objectId=2fc5e239870d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc5e239870d, replyNumber=0, likeNumber=100, createdTime=2022-04-12, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc5e239870d, moduleTitle=AACR重磅之SPOTLIGHT203试验：瘤内注射BO-112联合帕博丽珠单抗对PD-1免疫治疗耐药的晚期黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc5e239870d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565137, encodeId=d719156513e09, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=AACR重磅之SPOTLIGHT203试验：瘤内注射BO-112联合帕博丽珠单抗对PD-1免疫治疗耐药的晚期黑色素瘤患者的疗效, objectType=article, longId=723987, objectId=2fc5e239870d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc5e239870d, replyNumber=0, likeNumber=83, createdTime=2022-04-12, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc5e239870d, moduleTitle=AACR重磅之SPOTLIGHT203试验：瘤内注射BO-112联合帕博丽珠单抗对PD-1免疫治疗耐药的晚期黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc5e239870d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559127, encodeId=f343155912ecd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率, objectType=article, longId=302298, objectId=64843022983a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64843022983a, replyNumber=0, likeNumber=78, createdTime=2022-04-04, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64843022983a, moduleTitle=JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64843022983a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565136, encodeId=e3d8156513656, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率, objectType=article, longId=302298, objectId=64843022983a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64843022983a, replyNumber=0, likeNumber=92, createdTime=2022-04-04, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64843022983a, moduleTitle=JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64843022983a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559126, encodeId=95601559126f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, objectType=article, longId=302278, objectId=941a3022e85a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941a3022e85a, replyNumber=0, likeNumber=74, createdTime=2022-04-04, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941a3022e85a, moduleTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941a3022e85a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565135, encodeId=a92c156513550, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, objectType=article, longId=302278, objectId=941a3022e85a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941a3022e85a, replyNumber=0, likeNumber=86, createdTime=2022-04-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941a3022e85a, moduleTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941a3022e85a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559125, encodeId=dcea1559125a8, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究, objectType=article, longId=302063, objectId=7e953020633b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e953020633b, replyNumber=0, likeNumber=86, createdTime=2022-04-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e953020633b, moduleTitle=BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e953020633b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565134, encodeId=c37415651344c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究, objectType=article, longId=302063, objectId=7e953020633b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e953020633b, replyNumber=0, likeNumber=67, createdTime=2022-04-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e953020633b, moduleTitle=BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e953020633b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

黑色素

2020-05-29

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

ASCO：四周的MPRbx可作为晚期黑色素瘤治疗反应的早期生物标志物

2022-06-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

ASCO：四周的MPRbx可作为晚期黑色素瘤治疗反应的早期生物标志物

2022-06-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者

2022-06-01

zhouqu_8 (审核中...)

前往app查看评论内容

#黑色素#

ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者

2022-06-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果

2022-06-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果

2022-06-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义

2022-05-11

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义

2022-05-11

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JGH:长期使用硫嘌呤不会增加炎症性肠病患者淋巴瘤和非黑色素瘤皮肤癌的风险

2022-05-10

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JGH:长期使用硫嘌呤不会增加炎症性肠病患者淋巴瘤和非黑色素瘤皮肤癌的风险

2022-05-10

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）

2022-05-04

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）

2022-05-04

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

AACR重磅之SPOTLIGHT203试验：瘤内注射BO-112联合帕博丽珠单抗对PD-1免疫治疗耐药的晚期黑色素瘤患者的疗效

2022-04-12

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

AACR重磅之SPOTLIGHT203试验：瘤内注射BO-112联合帕博丽珠单抗对PD-1免疫治疗耐药的晚期黑色素瘤患者的疗效

2022-04-12

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率

2022-04-04

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率

2022-04-04

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）

2022-04-04

zhaojie88 (审核中...)

前往app查看评论内容

#黑色素#

NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）

2022-04-04

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究

2022-04-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究

2022-04-01

科室
- - 订阅+
  - 更多科室
工具
服务